Article

New Issue Alert: Genitourinary Cancers

We've got a sneak peek at what’s inside CURE®'s 2019 Genitourinary Cancers special issue.

Hi, I’m Jessica Skarzynski for CURE Magazine®, your guide to every stage of the cancer experience.

Here’s a look at what’s inside our 2019 Genitourinary Cancers special issue:

Active surveillance has become the gold standard for low-risk prostate cancer, but challenges remain. What new diagnostic tools can be used to make it more precise? In this issue’s cover story, we delve deeper into how experts are Polishing the Gold Standard.

Next, when it comes to treating kidney cancer — more may be better. A One-Two Punch approach, with immunotherapy and targeted treatment, offers a better alternative to single agents.

To read these stories and more, visit our Genitourinary Cancers Special Issue online.

Or, ensure you don’t miss a story when you subscribe to new issue alerts. Visit curetoday.com/email-profile for more information.

And, as always, thanks for reading.

Related Videos
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Image of man with black hair.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of man with brown and grey hair.
Dr. Kelly Stratton
Related Content